Upregulation of mitogen-activated protein kinase in ganglioglioma

Folia Neuropathologica

Volumn 51, Issue 4, 2013, Pages 283-289

  Rak, Beata ^a   Szlufik, Stanisław ^a   Grajkowska, Wiesława ^b,c   Perek, Danuta ^c   Dembowska Bagińska, Bozena ^c   Filipek, Iwona ^c   Daszkiewicz, Paweł ^c   Włodarski, Paweł ^a   Jóźwiak, Jarosław ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

^c CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

Author keywords

Akt; Erk; Ganglioglioma; MAPK

Indexed keywords

INITIATION FACTOR 4E BINDING PROTEIN 1; INSULIN RECEPTOR ALPHA; INSULIN RECEPTOR KINASE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PROTEIN KINASE B; PROTEIN S6; RHEB PROTEIN; RIBOSOMAL S6 KINASE 1; STRESS ACTIVATED PROTEIN KINASE 1; UNCLASSIFIED DRUG;

ARTICLE; BRAIN; CANCER LOCALIZATION; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; GLIOMA; HUMAN; HUMAN TISSUE; MALE; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING;

ADOLESCENT; BRAIN NEOPLASMS; CHILD; FEMALE; GANGLIOGLIOMA; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES; UP-REGULATION;

EID: 84891770547     PISSN: 16414640     EISSN: 1509572X     Source Type: Journal    
DOI: 10.5114/fn.2013.39717     Document Type: Article

References (25)

1. Aronica E, Boer K, Doorn KJ, Zurolo E, Spliet WG, van Rijen PC, Baayen JC, Gorter JA, Jeromin A. Expression and localization of voltage dependent potassium channel Kv4.2 in epilepsy associated focal lesions. Neurobiol Dis 2009; 36: 81-95.
2. Astrinidis A, Henske EP. Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease. Oncogene 2005; 24: 7475-7481.
3. Blümcke I, Giencke K, Wardelmann E, Beyenburg S, Kral T, Sarioglu N, Pietsch T, Wolf HK, Schramm J, Elger CE, Wiestler OD. The CD34 epitope is expressed in neoplastic and malformative lesions associated with chronic, focal epilepsies. Acta Neuropathol 1999; 97: 481-490.
4. Blümcke I, Wiestler OD. Gangliogliomas: an intriguing tumor entity associated with focal epilepsies. J Neuropathol Exp Neurol 2002; 61: 575-584.
5. Boer K, Troost D, Timmermans W, van Rijen PC, Spliet WG, Aronica E. Pi3K-mTOR signaling and AMOG expression in epilepsy-associated glioneuronal tumors. Brain Pathol 2010; 20: 234-244.
6. Chandrashekhar TN, Mahadevan A, Vani S, Yasha TC, Sampath S, Chandramouli BA, Devi BI, Arvinda HR, Shankar SK. Pathological spectrum of neuronal/glioneuronal tumors from a tertiary referral neurological Institute. Neuropathology 2012; 32: 1-12.
7. Crino PB. Focal brain malformations: a spectrum of disorders along the mTOR cascade. Novartis Found Symp 2007; 288: 260-272.
8. Curatolo P, Moavero R. mTOR inhibitors as a new therapeutic option for epilepsy. Expert Rev Neurother 2013; 13: 627-638.
9. Dan HC, Sun M, Yang L, Feldman RI, Sui XM, Ou CC, Nellist M, Yeung RS, Halley DJ, Nicosia SV, Pledger WJ, Cheng JQ. Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin. J Biol Chem 2002; 277: 35364-35370.
10. Deb P, Sharma MC, Tripathi M, Sarat Chandra P, Gupta A, Sarkar C. Expression of CD34 as a novel marker for glioneuronal lesions associated with chronic intractable epilepsy. Neuropathol Appl Neurobiol 2006; 32: 461-468.
11. Gelabert-González M, Amo JM, Arcos Algaba A, Serramito García R, Castro Bouzas D, Díaz Cabana L, Prieto González A, Aran Echabe E, Bandín Diéguez FJ, Villa Fernández J, García Allut A. Intracranial gangliogliomas. A review of a series of 20 patients. Neurologia 2011; 26: 405-415.
12. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 18: 1926-1945.
13. Holmes GL, Stafstrom CE; Tuberous Sclerosis Study Group. Tuberous sclerosis complex and epilepsy: recent developments and future challenges. Epilepsia 2007; 48: 617-630.
14. Jozwiak J, Jozwiak S, Wlodarski P. Possible mechanisms of disease development in tuberous sclerosis. Lancet Oncol 2008; 9: 73-79.
15. Jóźwiak J, Bikowska B, Grajkowska W, Sontowska I, Roszkowski M, Galus R. Activation of Akt/mTOR pathway in a patient with atypical teratoid/rhabdoid tumor. Folia Neuropathol 2010; 48: 185-189.
16. Kinkl N, Sahel J, Hicks D. Alternate FGF2-ERK1/2 signaling pathways in retinal photoreceptor and glial cells in vitro. J Biol Chem 2001; 276: 43871-43878.
17. Koelsche C, Wöhrer A, Jeibmann A, Schittenhelm J, Schindler G, Preusser M, Lasitschka F, von Deimling A, Capper D. Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells. Acta Neuropathol 2013; 125: 891-900.
18. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114: 97-109.
19. Majores M, Schick V, Engels G, Fassunke J, Elger CE, Schramm J, Blümcke I, Becker AJ. Mutational and immunohistochemical analysis of ezrin-, radixin-, moesin (ERM) molecules in epilepsy-associated glioneuronal lesions. Acta Neuropathol 2005; 110: 537-546.
20. McLendon RE, Provenzale J. Glioneuronal tumors of the central nervous system. Brain Tumor Pathol 2002; 19: 51-58.
21. Miller DC, Koslow M, Budzilovich GN, Burstein DE. Synaptophysin: a sensitive and specific marker for ganglion cells in central nervous system neoplasms. Hum Pathol 1990; 21: 271-276.
22. Prayson RA. Tumours arising in the setting of paediatric chronic epilepsy. Pathology 2010; 42: 426-431.
23. Quinn B. Synaptophysin staining in normal brain: importance for diagnosis of ganglioglioma. Am J Surg Pathol 1998; 22: 550-556.
24. Schick V, Majores M, Koch A, Elger CE, Schramm J, Urbach H, Becker AJ. Alterations of phosphatidylinositol 3-kinase pathway components in epilepsy-associated glioneuronal lesions. Epilepsia 2007; 48 Suppl 5: 65-73.
25. Yang I, Chang EF, Han SJ, Barry JJ, Fang S, Tihan T, Barbaro NM, Parsa AT. Early surgical intervention in adult patients with ganglioglioma is associated with improved clinical seizure outcomes. J Clin Neurosci 2011; 18: 29-33.